Abituzumab Antibody

SKU: orb1980707

Description

Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, which exhibits anti-cancer properties by inhibiting FAK, Akt, and ERK phosphorylation. It is utilized in prostate cancer research, with studies demonstrating its activity in both in vitro cell models and in vivo xenograft experiments.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1105038-73-0
• MW: 144.58 kDa
• Purity: 98.44% (SEC-HPLC)
• Target: Integrin

Bioactivity

• In Vitro:
  Methods: Prostate cancer cell lines were inoculated into 24-well plates and treated with Abituzumab (0.01, 0.1,1,10, 30,100μg/ml). The wound space was measured every 6 hours to observe the invasion and movement of cells. Results: Abituzumab inhibited the movement and invasion of PCa cells. Methods: Prostate cancer cell lines were treated with Abituzumab (100μg/ml) and incubated for 24h. Results: Abituzumab inhibited αV integrin expression and phosphorylation of FAK, Akt and ERK in LNCaP and C4-2B cells.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

EMD525797, EMD 525797, DI 17E6, DI17E6

Quick Database Links

Gene Symbol

Integrin